Acelyrin (NASDAQ:SLRN - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.86) by $0.07, Zacks reports.
Acelyrin Stock Performance
SLRN traded down $0.02 on Friday, hitting $2.75. 1,392,082 shares of the company were exchanged, compared to its average volume of 1,209,203. Acelyrin has a fifty-two week low of $1.85 and a fifty-two week high of $7.30. The firm has a market capitalization of $275.90 million, a P/E ratio of -1.12 and a beta of 1.25. The business's fifty day moving average is $2.29 and its 200 day moving average is $3.81.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on the stock. Wells Fargo & Company dropped their price target on shares of Acelyrin from $15.00 to $13.00 and set an "overweight" rating on the stock in a research note on Wednesday, December 11th. HC Wainwright lowered their target price on shares of Acelyrin from $8.00 to $6.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. Finally, Citigroup lowered their target price on shares of Acelyrin from $6.00 to $3.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $9.60.
Get Our Latest Report on Acelyrin
Insider Buying and Selling at Acelyrin
In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $2.74, for a total value of $49,281.64. Following the sale, the chief executive officer now owns 671,753 shares of the company's stock, valued at $1,840,603.22. This represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 13.60% of the company's stock.
Acelyrin Company Profile
(
Get Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Further Reading
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
